| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/11/2006 | WO2006049433A1 Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion |
| 05/11/2006 | WO2006049307A1 Liposome and method of injecting substance into cell by using the same |
| 05/11/2006 | WO2006049078A1 Drug for external use for treating skin disease |
| 05/11/2006 | WO2006049032A1 Preparation of nanogel-apatite composite |
| 05/11/2006 | WO2006048639A1 Hydrogel delivery vehicle |
| 05/11/2006 | WO2006048601A1 Thermally responsive polymers |
| 05/11/2006 | WO2006048501A1 A transmucosal veterinary composition comprising detomidine |
| 05/11/2006 | WO2006048452A2 Peptides for use in treating of obesity |
| 05/11/2006 | WO2006048451A1 Peptides for use in the treatment of obesity |
| 05/11/2006 | WO2006048450A2 Peptides for use in the treating obesity |
| 05/11/2006 | WO2006048295A1 Composition compri sing vlp and amyloid - beta peptide |
| 05/11/2006 | WO2006048194A1 Stable aqueous formulation of a platin derivative |
| 05/11/2006 | WO2006047871A1 Encapsulated bacteriophage formulation |
| 05/11/2006 | WO2006031720A3 D-methionine formulation with improved biopharmaceutical properties |
| 05/11/2006 | WO2006030450A3 Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
| 05/11/2006 | WO2006027685A3 Glycosylceramide adjuvant for saccharide antigens |
| 05/11/2006 | WO2006026458A3 Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle |
| 05/11/2006 | WO2006005759A3 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| 05/11/2006 | WO2005120407A3 Preparation for localized delivery of therapeutic agent |
| 05/11/2006 | WO2005117977A8 Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface |
| 05/11/2006 | WO2005112887A3 Composition comprising intercalated functional-active organic compounds |
| 05/11/2006 | WO2005106471A3 Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4) |
| 05/11/2006 | WO2005102275B1 Galantamine salts, method of producing it and nasal composition thereof |
| 05/11/2006 | WO2005065713A3 Topically applied medicament for animals |
| 05/11/2006 | WO2005003177A3 Molecules for the targeting and the in situ assembly of therapeutic proteins and use thereof |
| 05/11/2006 | WO2004056323A3 Method of treating angiogenic tissue growth |
| 05/11/2006 | WO2002055100A9 Method and composition for inhibition of tumor growth and enhancing an immune response |
| 05/11/2006 | US20060100370 Random and non-random alkylene oxide polymer alloy compositions |
| 05/11/2006 | US20060100369 Bifunctional-modified hydrogels |
| 05/11/2006 | US20060100172 Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type II diabetes |
| 05/11/2006 | US20060100163 Oligosaccharides linked by amide, imine,ether, ester, carbonate, carbamate, urea, thioester bond to active agent produce hydrophilicity; easily produced with homogeneity, predictable, desirable pharmacokinetic profile, enhanced biocompatibility |
| 05/11/2006 | US20060100149 Conjugates of membrane translocating agents and pharmaceutically active agents |
| 05/11/2006 | US20060100144 Conjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol) |
| 05/11/2006 | US20060100141 Administering peptidic or peptidomimetic compound having segment competent for importation of molecule into mast cells, and asecond segment for having an anti-allergic effect within mast cells for reducing late phase inflammatory responses induced by mitogen activated protein kinase activation |
| 05/11/2006 | US20060100139 Pharmaceutical used for treating HIV infection, the composition and uses thereof |
| 05/11/2006 | US20060100137 Monodispersed insulin polypeptide-oligomer conjugates; for administering by mouth an effective amount of an insulin polypeptide derivative within one hour of ingestion of a meal by the patient to provide an insulin drug concentration in portal vein blood of 10-1,000 U/ml within 60 minutes |
| 05/11/2006 | US20060100134 fusion proteins; drug delivery |
| 05/11/2006 | US20060099660 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| 05/11/2006 | US20060099652 IL 13 receptor alpha 2 antibody and methods of use |
| 05/11/2006 | US20060099324 Composition comprising viscous fibers and viscosity-lowering proteins |
| 05/11/2006 | US20060099278 Formulations containing melatonin, ginkgo biloba, and biotin |
| 05/11/2006 | US20060099276 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 05/11/2006 | US20060099271 Contacting microparticles og biodegradable, biocompatible polymer matrix comprising a peptide with halogenated solvent with nonaqueous washing system |
| 05/11/2006 | US20060099265 Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer |
| 05/11/2006 | US20060099264 biodegradable; biocompatible; colloids |
| 05/11/2006 | US20060099257 Controlled drug delivery systems providing variable release rates |
| 05/11/2006 | US20060099255 solid dosage forms for oral administration, reducing the range in daily dosages required to control pain in human patients |
| 05/11/2006 | US20060099232 Active oxygen eliminator and production method thereof |
| 05/11/2006 | US20060099227 Treating a skin wrinkle; reduced toxicity and/or a reduced immunogenicity, storage stability; e.g. hydroxyethyl Starch |
| 05/11/2006 | US20060099213 Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| 05/11/2006 | US20060099197 identifying a mammalian subject having an infection with said pathogenic Clostridium bacterium resistant to antibiotic, orally administering a therapeutically-effective concentration of Bacillus coagulans bacteria; reducing gastrointestinal colonization by a pathogenic Clostridium bacterium |
| 05/11/2006 | US20060099157 Ether alcohols used as solvents and emulsifiers and dispersions containing said ether alcohols |
| 05/11/2006 | US20060099150 Compositions and methods for the transport of biologically active agents across cellular barriers |
| 05/11/2006 | US20060099141 Radiation sensitive liposomes |
| 05/11/2006 | US20060096594 Actuation indicator for a dispensing device |
| 05/11/2006 | US20060096522 Apparatus and process for preparing crystalline particles |
| 05/11/2006 | DE3943807B4 Prepn. for iron supply - comprises specified amts. of specified iron contg. cpd., sodium carbonate or bi:carbonate and a neutralising agent |
| 05/11/2006 | DE19715477B4 Verfahren und Vorrichtung zur Herstellung hartmagnetischer Einbereichsteilchen mit hoher Koerzitivfeldstärke Method and apparatus for the production of hard magnetic single-domain particles with high coercivity |
| 05/11/2006 | DE102004054536A1 Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel Multimodal modified cells as cellular forms for active substances and as diagnostic cell particles |
| 05/11/2006 | DE10055742B4 Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen New polyester, process for their preparation and depot dosage forms prepared from the polyesters |
| 05/11/2006 | CA2588260A1 Glycan analysis using deuterated glucose |
| 05/11/2006 | CA2586611A1 Encapsulated bacteriophage formulation |
| 05/11/2006 | CA2585866A1 Stable aqueous formulation of a platin derivative |
| 05/11/2006 | CA2585855A1 Dye-free pharmaceutical suspensions comprising sorbitol as a non-reducing sweetener and at least one active agent |
| 05/11/2006 | CA2585471A1 Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| 05/11/2006 | CA2585114A1 Antiviral composition |
| 05/11/2006 | CA2583517A1 Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkaline agent for enhanced absorption |
| 05/11/2006 | CA2581300A1 Composition comprising vlp and amyloid-beta peptide |
| 05/10/2006 | EP1655361A1 Contaminant reduced marine oil |
| 05/10/2006 | EP1655039A2 Immunoliposomes that optimize internalization into target cells |
| 05/10/2006 | EP1655038A1 Target-directed and enteric absorption-controlled liposome having sugar chain and cancer remedy and diagnostic containing the same |
| 05/10/2006 | EP1655023A1 Botulinum toxin implat |
| 05/10/2006 | EP1655022A1 Remedy or diagnostic for inflammatory disease containing target-directing liposome |
| 05/10/2006 | EP1654302A1 Thermosensitive poly (organophosphazenes), preparation method thereof and injectable thermosensitive polyphosphazene hydrogels using the same |
| 05/10/2006 | EP1654290A1 Sialic acid derivatives for protein derivatisation and conjugation |
| 05/10/2006 | EP1654289A1 Polysialic acid derivatives |
| 05/10/2006 | EP1654003A2 Preventative effects of morinda citrifolia on mammary breast cancer |
| 05/10/2006 | EP1653991A2 Conjugates of a polymer and a protein linked by an oxime linking group |
| 05/10/2006 | EP1653988A2 Leukocyte internalized peptide-drug conjugates |
| 05/10/2006 | EP1653975A1 Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers |
| 05/10/2006 | EP1653963A1 Nasal pharmaceutical composition of piribedil |
| 05/10/2006 | EP1653933A1 Dermal or transdermal therapeutic system comprising an ormocer with barrier effect on a cover foil |
| 05/10/2006 | EP1653927A2 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| 05/10/2006 | EP1653895A1 Condom with a coating and composition |
| 05/10/2006 | EP1653815A1 Methods for reducing astringency |
| 05/10/2006 | EP1483374B1 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vitro |
| 05/10/2006 | EP1478383A4 Compositions and methods for promoting myocardial and peripheral angiogenesis |
| 05/10/2006 | EP1416969A4 Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| 05/10/2006 | EP1411765A4 Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants |
| 05/10/2006 | EP1210355B1 Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof |
| 05/10/2006 | EP1154798B1 Molecules for the treatment and diagnosis of tumors |
| 05/10/2006 | EP1145001B1 (in vitro) model for gastrointestinal inflammation |
| 05/10/2006 | EP1069916B1 Latent reactive blood compatible agents |
| 05/10/2006 | EP1015026B1 Il-12 as an adjuvant for bordetella pertussis vaccines |
| 05/10/2006 | EP0765357B9 Antiviral dendrimers |
| 05/10/2006 | CN1771262A Titanium dioxide complex having molecule distinguishability |
| 05/10/2006 | CN1771057A Releasable polymeric conjugates based on biodegradable linkers |
| 05/10/2006 | CN1771041A Prostaglandin compositions for the treatment of erectile dysfunction |
| 05/10/2006 | CN1768861A Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 05/10/2006 | CN1768860A Method for assembling multi-biological functional factor on micro-particle surface based on hydrazide group |